{ "schemaVersion": 1, "organisationId": "O-2747aa29f5bc45ecb77792c672fe8940", "slug": "haemonetics-corp", "name": "HAEMONETICS CORP", "updatedAt": "2026-10-02T13:16:40.662408Z", "sections": [ { "type": "OVERVIEW", "text": "Haemonetics is a medical-technology company that develops, manufactures and markets products for blood and plasma collection, blood management, and interventional care. Its businesses are organized into Plasma, Blood Center and Hospital segments, with offerings including collection systems and disposables, blood-processing technologies, and hospital products for vascular closure, cell salvage and transfusion management. [P65292316][P32187277][P74630292][P14099035]\n\nThe company’s stated purpose is “We make it possible. You make it matter,” and its mission is to develop medical-technology products and services that improve the quality, effectiveness and efficiency of care. [https://www.haemonetics.com/en/about-us/purpose-mission-and-values] In fiscal 2026, Haemonetics reported $1.334 billion in net revenue and 3,009 full-time-equivalent employees; it marketed and sold products in approximately 90 countries. [T213496][https://www.haemonetics.com/en/about-us/corporate-responsibility/modern-slavery-act-transparency-statement][P87294986]\n[P65292316][P32187277][P74630292][P14099035][https://www.haemonetics.com/en/about-us/purpose-mission-and-values][T213496][https://www.haemonetics.com/en/about-us/corporate-responsibility/modern-slavery-act-transparency-statement][P87294986][https://www.haemonetics.com/en/about-us/purpose-mission-and-values][https://www.haemonetics.com/en/about-us/corporate-responsibility/modern-slavery-act-transparency-statement]", "updatedAt": "2026-10-02T13:16:40.662408Z" }, { "type": "PRODUCTS", "text": "Haemonetics’ Plasma products include the NexSys PCS plasmapheresis system and associated disposables, plus collection technologies intended to increase plasma yield or tailor collection to the donor. YES technology adds an average of 18–26 mL per donation; Persona adjusts collection to donor body composition and reports an average 9–12% increase in plasma volume versus its stated baseline. Persona PLUS received FDA clearance in FY2026, while Express Plus was designed to reduce procedure time. The company also offers NexLynk DMS and Donor360 software for donor qualification, center workflows, suitability controls, unit release and distribution, and donor engagement. [P23099134][P26365784][P43671961]\n\nBlood Center products include MCS apheresis equipment, which collects selected blood components and can collect multiple doses or combinations, and the ACP automated cell processor, which prepares and recovers frozen blood cells. In Hospital, VASCADE devices close vascular access sites using catheter delivery and collagen; the product family includes VASCADE 5F, 6/7F, MVP and MVP XL. OptoWire measures fractional flow reserve and diastolic pressure ratio, while SavvyWire combines a TAVR guidewire with hemodynamic measurement, display and left-ventricular pacing. The ensoETM circulates temperature-controlled water through an esophageal tube to cool patients during radiofrequency cardiac ablation and can also cool or warm patients in other care settings. PerQseal Elite is a bioabsorbable, sutureless closure patch for large-bore access sites, described for arteriotomies or venotomies up to 26F. [P74630292][P61698798][P76879082][P103189046][P25211567][P21213326][P2506897]\n\nOther Hospital products include TEG 6s viscoelastic testing, which assesses hemostasis and supports evaluation of hemorrhage and thrombosis; its PlateletMapping cartridge assesses platelet function, and Global Hemostasis-HN enables testing in fully heparinized patients in specified settings. Cell Saver Elite+ recovers and prepares a patient’s own blood for reinfusion during surgeries with medium or high blood loss. In FY2026, Plasma represented 39.3% of company revenue and Blood Center represented 16.6%; the report does not provide individual product revenue percentages. [P70237816][P48282365][P14099035]\n[P23099134][P26365784][P43671961][P74630292][P61698798][P76879082][P103189046][P25211567][P21213326][P2506897][P70237816][P48282365][P14099035]", "updatedAt": "2026-10-02T13:16:40.662408Z" }, { "type": "GEOGRAPHY", "text": "In FY2026, Haemonetics reported revenue by principal operating region as follows: United States, 73.6%; Europe, 13.9%; Rest of Asia, 6.5%; Japan, 5.1%; and Other, 0.9%. [P6181359] The company’s global headquarters are in Boston, Massachusetts. [P93061037]\n\nPrincipal manufacturing centers are in Pennsylvania and in Malaysia, Mexico, Canada, and Ireland. Primary distribution centers are in Utah and Pennsylvania, with smaller facilities elsewhere globally; facilities in the United States, Malaysia, and Mexico serve multiple business segments. [P93061037] International sales are generally made in local currencies, primarily Japanese yen, euros, and Chinese yuan. [P105841292]\n[P6181359][P93061037][P105841292]", "updatedAt": "2026-10-02T13:16:40.662408Z" }, { "type": "SEGMENTS", "text": "Haemonetics reports three principal business segments. **Plasma** provides plasma-collection devices and disposables, donor-management software, and related software; it generated $524.5 million, approximately **39.3%** of FY2026 revenue. **Blood Center** supplies blood-collection and processing devices and disposables for plasma, red cells, and platelets; it generated $221.3 million, approximately **16.6%**. **Hospital** comprises Interventional Technologies (Vascular Closure, Sensor-Guided Technologies, and Esophageal Protection) and Blood Management Technologies (Hemostasis Management, Cell Salvage, and Transfusion Management); it generated $588.3 million, approximately **44.1%**. Shares are calculated from segment revenue and consolidated revenue of $1,334.0 million for the fiscal year ended March 28, 2026. [P70774979][T10751315]\n[P70774979][T10751315][T10751315][T10751315][T10751315]", "updatedAt": "2026-10-02T13:16:40.662408Z" }, { "type": "HISTORY", "text": "Founded in 1971 by Allen “Jack” Latham Jr., Haemonetics grew from his work on automated blood-component separation. It introduced the Cell Saver system in 1974, opened its first international headquarters in 1981, launched the PCS plasma-collection system in 1984, and went public on the New York Stock Exchange in 1991. [https://www.nae.edu/19579/19581/20412/29027/mr-allen-latham-jr] [https://www.haemonetics.com/en/about-us]\n\nFrom 2000 onward, the company expanded beyond its original blood-component technologies through acquisitions, including Transfusion Technologies (2000), TEG hemostasis-analyzer assets (2007), Pall’s transfusion-medicine business (2012), Cardiva Medical (2021) and OpSens (2023). [https://www.sec.gov/Archives/edgar/data/313143/000091064700500102/hae-8ka.txt] [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-tegr-hemostasis-analyzer] [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-palls-transfusion-medicine/] [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-acquire-cardiva-medical-inc-expand-hospital] [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-corporation-completes-acquisition-opsens-inc/]\n\nIn 2024, Haemonetics announced the sale of its whole-blood product line and related assets to GVS; the sale was completed in January 2025. In February 2026, it announced FDA clearance for NexSys PCS with Persona PLUS technology. [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-sale-whole-blood-assets-gvs-spa] [https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-receives-fda-clearance-nexsysr-pcs-plasma-collection]\n[https://www.nae.edu/19579/19581/20412/29027/mr-allen-latham-jr][https://www.haemonetics.com/en/about-us][https://www.sec.gov/Archives/edgar/data/313143/000091064700500102/hae-8ka.txt][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-tegr-hemostasis-analyzer][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-palls-transfusion-medicine/][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-acquire-cardiva-medical-inc-expand-hospital][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-corporation-completes-acquisition-opsens-inc/][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-sale-whole-blood-assets-gvs-spa][https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-receives-fda-clearance-nexsysr-pcs-plasma-collection]", "updatedAt": "2026-10-02T13:16:40.662408Z" } ], "sources": [ { "id": "P65292316", "href": "https://app.finbar.com/go?id=P65292316", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P32187277", "href": "https://app.finbar.com/go?id=P32187277", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P74630292", "href": "https://app.finbar.com/go?id=P74630292", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P14099035", "href": "https://app.finbar.com/go?id=P14099035", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "https://www.haemonetics.com/en/about-us/purpose-mission-and-values", "href": "https://www.haemonetics.com/en/about-us/purpose-mission-and-values", "label": "www.haemonetics.com" }, { "id": "T213496", "href": "https://app.finbar.com/go?id=T213496", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "https://www.haemonetics.com/en/about-us/corporate-responsibility/modern-slavery-act-transparency-statement", "href": "https://www.haemonetics.com/en/about-us/corporate-responsibility/modern-slavery-act-transparency-statement", "label": "www.haemonetics.com" }, { "id": "P87294986", "href": "https://app.finbar.com/go?id=P87294986", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P23099134", "href": "https://app.finbar.com/go?id=P23099134", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P26365784", "href": "https://app.finbar.com/go?id=P26365784", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P43671961", "href": "https://app.finbar.com/go?id=P43671961", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P61698798", "href": "https://app.finbar.com/go?id=P61698798", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P76879082", "href": "https://app.finbar.com/go?id=P76879082", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P103189046", "href": "https://app.finbar.com/go?id=P103189046", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P25211567", "href": "https://app.finbar.com/go?id=P25211567", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P21213326", "href": "https://app.finbar.com/go?id=P21213326", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P2506897", "href": "https://app.finbar.com/go?id=P2506897", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P70237816", "href": "https://app.finbar.com/go?id=P70237816", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P48282365", "href": "https://app.finbar.com/go?id=P48282365", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P6181359", "href": "https://app.finbar.com/go?id=P6181359", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P93061037", "href": "https://app.finbar.com/go?id=P93061037", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P105841292", "href": "https://app.finbar.com/go?id=P105841292", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "P70774979", "href": "https://app.finbar.com/go?id=P70774979", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "T10751315", "href": "https://app.finbar.com/go?id=T10751315", "label": "HAEMONETICS CORP — Full financial report (2026 Y)", "documentId": "D-e2b901194b63406783313224e65aeacb" }, { "id": "https://www.nae.edu/19579/19581/20412/29027/mr-allen-latham-jr", "href": "https://www.nae.edu/19579/19581/20412/29027/mr-allen-latham-jr", "label": "www.nae.edu" }, { "id": "https://www.haemonetics.com/en/about-us", "href": "https://www.haemonetics.com/en/about-us", "label": "www.haemonetics.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/313143/000091064700500102/hae-8ka.txt", "href": "https://www.sec.gov/Archives/edgar/data/313143/000091064700500102/hae-8ka.txt", "label": "www.sec.gov" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-tegr-hemostasis-analyzer", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-tegr-hemostasis-analyzer", "label": "haemonetics.gcs-web.com" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-palls-transfusion-medicine/", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-acquisition-palls-transfusion-medicine/", "label": "haemonetics.gcs-web.com" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-acquire-cardiva-medical-inc-expand-hospital", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-acquire-cardiva-medical-inc-expand-hospital", "label": "haemonetics.gcs-web.com" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-corporation-completes-acquisition-opsens-inc/", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-corporation-completes-acquisition-opsens-inc/", "label": "haemonetics.gcs-web.com" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-sale-whole-blood-assets-gvs-spa", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-completes-sale-whole-blood-assets-gvs-spa", "label": "haemonetics.gcs-web.com" }, { "id": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-receives-fda-clearance-nexsysr-pcs-plasma-collection", "href": "https://haemonetics.gcs-web.com/news-releases/news-release-details/haemonetics-receives-fda-clearance-nexsysr-pcs-plasma-collection", "label": "haemonetics.gcs-web.com" } ] }